biologic

Gammaplex

Immune Globulin Intravenous (Human)

Loss of exclusivityFebruary 2029projected — 12-year biologic exclusivity estimate
CompanyBio Products Laboratory Limited

Drug detail

Brand nameGammaplex
Active ingredientImmune Globulin Intravenous (Human)
Strength20G/200ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2017
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Gammaplex patent cliff — loss of exclusivity February 2029 | CliffBio